Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AKRINOL vs BYQLOVI
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Not available; likely a combination product with antihistaminic and sympathomimetic actions.
BYQLOVI (revumenib) is a menin inhibitor that binds to the menin protein, blocking its interaction with mixed lineage leukemia (MLL) fusion proteins and thus inhibiting leukemogenesis.
Allergic rhinitis,Nasal congestion
Treatment of relapsed or refractory acute leukemia with a lysine methyltransferase 2A (KMT2A) gene translocation in adults and pediatric patients 1 year and older
Adults: 100 mg orally twice daily.
BYQLOVI (bictegravir/emtricitabine/tenofovir alafenamide) is administered orally as a single tablet (50/200/25 mg) once daily with or without food.
3-4 hours (prolonged to 8-12 hours in renal impairment; no dose adjustment typically needed unless Cr Cl <30 m L/min).
Terminal elimination half-life is approximately 12 hours (range 10–14 hours) in patients with normal renal function; prolonged in renal impairment.
Not available; components may be metabolized via hepatic CYP enzymes.
Primarily metabolized by CYP3A4 and CYP2D6.
Primarily renal (80-90% as unchanged drug via glomerular filtration and tubular secretion); minor biliary/fecal (5-10%).
Renal excretion of unchanged drug accounts for approximately 95% of elimination; fecal excretion is minimal (<5%).
99.5% (primarily to albumin; also to α1-acid glycoprotein).
Approximately 85% bound to serum albumin.
0.10-0.17 L/kg (low, indicating limited extravascular distribution; primarily in central compartment).
Volume of distribution is about 0.6 L/kg, indicating distribution into total body water.
Oral: 3-5% (extensive first-pass metabolism); IV: 100%.
Oral bioavailability is approximately 80% (range 75–85%) under fasting conditions; food may reduce absorption.
GFR 30-59 m L/min: 50 mg daily; GFR <30 m L/min: 50 mg every other day.
Contraindicated in patients with estimated creatinine clearance (Cr Cl) <30 m L/min. No dose adjustment required for Cr Cl ≥30 m L/min.
Child-Pugh A: 100 mg twice daily; Child-Pugh B: 50 mg twice daily; Child-Pugh C: 50 mg daily.
Not recommended in patients with severe hepatic impairment (Child-Pugh Class C). No dose adjustment required for mild (Child-Pugh Class A) or moderate (Child-Pugh Class B) hepatic impairment.
Children (1-12 years): 2 mg/kg orally twice daily, max 100 mg/dose.
For adolescents aged ≥12 years and weighing ≥35 kg, administer one tablet (50/200/25 mg) orally once daily. Safety and efficacy not established in pediatric patients <12 years or <35 kg.
Adults >65 years: initiate at 50 mg twice daily, titrate to 100 mg twice daily as tolerated.
No specific dose adjustment recommended in elderly patients. Monitor renal function due to age-related decline.
None
No FDA boxed warning reported.
Use with caution in patients with hypertension,Avoid in patients with severe coronary artery disease
Differentiation syndrome, which may be life-threatening or fatal; if suspected, initiate corticosteroids and hemodynamic monitoring.,QTc interval prolongation; monitor electrolytes and electrocardiograms.,Embryo-fetal toxicity.
Hypersensitivity to any component,Severe hypertension,Concomitant use with MAO inhibitors
None reported.
No known food interactions with topical naftifine. No dietary restrictions required.
Avoid grapefruit, grapefruit juice, Seville oranges, and starfruit as they inhibit CYP3A4 and can increase drug levels, leading to toxicity. No other known food interactions. Take with or without food, but consistent timing and fat content is recommended to maintain stable exposure.
FDA Pregnancy Category D. First trimester: risk of CNS defects and spontaneous abortion. Second/third trimester: risk of premature closure of ductus arteriosus, oligohydramnios, renal dysfunction, necrotizing enterocolitis, periventricular hemorrhage, and pulmonary hypertension.
BYQLOVI (bictegravir/emtricitabine/tenofovir alafenamide) is contraindicated in pregnancy due to risk of neural tube defects (NTDs) observed with dolutegravir-containing regimens in first trimester exposure. In animal studies, no evidence of teratogenicity at clinically relevant exposures. Human data: insufficient for risk assessment; case reports of NTDs with bictegravir insufficient to rule out. First trimester: potential for NTDs, avoid unless benefit outweighs risk. Second/third trimester: limited data, no specific fetal risks identified, but use alternative if possible.
Contraindicated during breastfeeding. M/P ratio not determined due to contraindication. Excreted into breast milk; potential for serious adverse effects in infant.
Breastfeeding not recommended during BYQLOVI therapy due to potential for HIV-1 transmission via breast milk and unknown effects in infants. Bictegravir excretion into human milk unknown; emtricitabine: M/P ratio ~0.6; tenofovir alafenamide: M/P ratio ~0.3 (tenofovir). Limited data: low levels may be excreted. HIV-positive mothers should not breastfeed to avoid transmission.
No established safe dose. Generally contraindicated during pregnancy. If used, lowest effective dose and shortest duration. Avoid after 20 weeks gestation.
No specific dosing adjustments recommended during pregnancy due to limited data. Pharmacokinetic studies in pregnancy are lacking. Bictegravir AUC may decrease in second and third trimester; clinical relevance unknown. Consider alternative antiretroviral regimens with established safety data in pregnancy (e.g., dolutegravir plus emtricitabine/tenofovir disoproxil fumarate).
AKRINOL is a topical antifungal (naftifine) that inhibits squalene epoxidase, effective against dermatophytes. Apply once daily for 2-4 weeks. Avoid occlusive dressings. Monitor for local irritation or allergic contact dermatitis.
BYQLOVI (bruton tyrosine kinase inhibitor) is indicated for chronic lymphocytic leukemia (CLL) and Waldenström macroglobulinemia. Monitor for atrial fibrillation, hypertension, and bleeding risk. Administer with a full glass of water and do not crush or open capsules. Dose reduction may be needed with strong CYP3A4 inhibitors. Avoid concurrent use with warfarin or other anticoagulants if possible.
Apply a thin layer to the affected area once daily, usually for 2 to 4 weeks.,Wash hands before and after application unless treating the hands.,Do not cover the treated area with bandages or wraps unless directed.,Avoid contact with eyes, nose, mouth, or broken skin. If contact occurs, rinse with water.,Notify your doctor if condition worsens, does not improve within 4 weeks, or if severe irritation or allergic reaction develops.
Take exactly as prescribed, with a full glass of water.,Do not open, break, or chew the capsules; swallow whole.,Avoid grapefruit, grapefruit juice, Seville oranges, and starfruit while on this medication.,Report any signs of bleeding (e.g., unusual bruising, black stools) or irregular heartbeat immediately.,Avoid activities that may cause injury due to increased bleeding risk.,Use effective contraception during treatment and for at least 1 month after the last dose.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AKRINOL vs BYQLOVI, answered by our medical review team.
AKRINOL is a Topical Retinoid that works by Not available; likely a combination product with antihistaminic and sympathomimetic actions.. BYQLOVI is a Topical Retinoid that works by BYQLOVI (revumenib) is a menin inhibitor that binds to the menin protein, blocking its interaction with mixed lineage leukemia (MLL) fusion proteins and thus inhibiting leukemogenesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AKRINOL and BYQLOVI depend on the specific clinical indication. These are both Topical Retinoid agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AKRINOL is: Adults: 100 mg orally twice daily.. The standard adult dose of BYQLOVI is: BYQLOVI (bictegravir/emtricitabine/tenofovir alafenamide) is administered orally as a single tablet (50/200/25 mg) once daily with or without food.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AKRINOL and BYQLOVI in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AKRINOL is classified as Category C. FDA Pregnancy Category D. First trimester: risk of CNS defects and spontaneous abortion. Second/third trimester: risk of premature closure of ductus arteriosus, oligohydramnios, re. BYQLOVI is classified as Category C. BYQLOVI (bictegravir/emtricitabine/tenofovir alafenamide) is contraindicated in pregnancy due to risk of neural tube defects (NTDs) observed with dolutegravir-containing regimens i. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.